MDXXF (Pharmala Biotech Holdings) EPS (Basic): $-0.01 (TTM As of Feb. 2026)


MDXXF Pharmala Biotech Holdings Inc MDXXF
35 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharmala Biotech Holdings EPS (Basic)?

Pharmala Biotech Holdings MDXXF +7.74% 35 EPS (Basic) is $-0.01 as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 35/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Pharmala Biotech Holdings's basic earnings per share (Basic EPS) for the three months ended in Feb. 2026 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.01.

Pharmala Biotech Holdings's EPS (Diluted) for the three months ended in Feb. 2026 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.01.

Pharmala Biotech Holdings's EPS without NRI for the three months ended in Feb. 2026 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2026 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was -23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Pharmala Biotech Holdings's highest 3-Year average EPS without NRI Growth Rate was 30.70% per year. The lowest was -23.90% per year. And the median was 3.40% per year.

Pharmala Biotech Holdings  (OTCPK:MDXXF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pharmala Biotech Holdings EPS (Basic) Related Terms

Pharmala Biotech Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings EPS (Basic) Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
EPS (Basic)
-0.02 -0.01 -0.01 -0.01 -0.01

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 0.00 -0.01 0.00
MDXXF
35GF Score
Pharmala Biotech Holdings Inc MDXXF
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pharmala Biotech Holdings's Basic EPS for the fiscal year that ended in Aug. 2025 is calculated as

Basic EPS (A: Aug. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.576-0)/99.576
=-0.02

Pharmala Biotech Holdings's Basic EPS for the quarter that ended in Feb. 2026 is calculated as

Basic EPS (Q: Feb. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.248-0)/108.885
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.01 mean?
Pharmala Biotech Holdings (MDXXF) has a EPS (Basic) of $-0.01 as of Feb. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' EPS (Basic) too high?
Pharmala Biotech Holdings' current EPS (Basic) is $-0.01. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' EPS (Basic) compare to VRTX and REGN?
Pharmala Biotech Holdings' EPS (Basic) of $-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current EPS (Basic) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current EPS (Basic) is $-0.01. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current EPS (Basic) is $-0.01 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • EPS (Basic): $-0.01
  • GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score

Get the complete analysis for MDXXF

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value